All-trans retinoic acid, which induces the differentiation of acute myeloid leukemia and is used in leukemia treatment, has been studied in combination with several epigenetic regulators, including inhibitors of HDAC and LSD1 [42, 43]. This evidence concerns the gene HDAC9 and acute myeloid leukemia.